Application of calmodulin as new target in prevention and treatment of diabetic lower limb peripheral vascular diseases

The invention discloses a new target spot for preventing and treating diabetic vascular complications and application of the new target spot in diabetic lower limb peripheral vascular diseases. The invention discloses a novel target for preventing and treating vascular complications of diabetes, namely calmodulin (CaM), and the down-regulation of the expression level of the calmodulin in vascular endothelium is an important reason for vascular endothelial injury of diabetes. The gene therapy of the adeno-associated virus carrying the CALM1 can reverse the expression of CaM of vascular endothelium of diabetes, enhance the activity of nitric oxide synthase and the generation of nitric oxide and vascular endothelial growth factors, promote angiogenesis and prevent and treat vascular complications of diabetes. The invention also clarifies the molecular mechanism of the low molecular weight fucoidan (LMWF) for treating the diabetic vascular complications, that is, the LMWF alleviates the down-regulation of CaM exp